What might the mechanisms behind circadian dysfunction in the early stages of dementia be? What more needs to be done to successfully translate this into the clinic? Watch our video with Marco Brancaccio to find out.
Browsing: Cognitive/neurodegenerative disorders
At the UK–Korea Neuroscience Symposium (12–13 August, London, UK), we had the fantastic opportunity of interviewing Justin Lee (Institute for…
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
A woman genetically predisposed to have early-onset autosomal dominant Alzheimer’s disease at the age of 40 did not display symptoms until her 70s. This has been linked to the presence of a rare gene variant termed APOE3ch.
In this video, we spoke with Kei Cho (UK DRI, King’s College London, UK) to find out more about the UK–Korea Neuroscience Symposium and how this collaboration has developed over the last few years.
Four studies presented at SfN Neuroscience have demonstrated how the microbiome interacts with the brain in mice, revealing the possible mechanisms behind gut–brain communication.
Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
Abstracts presented at SfN Neuroscience 2019 have revealed that metabolic disturbances in the brain could exacerbate and forewarn Alzheimer’s pathology in mice.
A recent study on the relationship between the huntingtin mutation and astrocytes has revealed that inhibition of the mutation in the glial cells could stop disease progression.